BC Week In Review | Aug 15, 2011
Clinical News

V7: Phase II started

Immune Network said its Immunitor Inc. business began the double-blind, Ukrainian Phase II imm02 trial to evaluate once-daily oral V7 plus standard of care (SOC) vs. placebo plus SOC in about 40 TB patients. Immune...
BC Week In Review | Feb 7, 2011
Company News

Immune Network, Immunitor deal

Immune Network plans to acquire Immunitor in a stock exchange deal. Immune Network will receive 50% of Immunitor's stock in exchange for 50 million Immune Network shares, valued at $2.1 million based on Immune Network's...
BC Week In Review | Jan 31, 2011
Clinical News

V-5 Immunitor: Interim Phase IIb data

Interim data from 34 patients at a second clinical site in the ongoing, double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard of care (SOC) led to a significantly higher...
BC Week In Review | Jan 3, 2011
Clinical News

V-5 Immunitor: Interim Phase IIb data

Interim data from 55 evaluable patients in the double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard of care (SOC) met the primary endpoint of a significantly greater proportion of...
BC Extra | Dec 30, 2010
Clinical News

Immunitor's V5 meets TB endpoint

Immunitor Inc. (College Park, Md.) said once-daily oral V5 plus standard of care (SOC) met the primary endpoint of a significantly greater proportion of patients with a negative sputum smear at one month vs. placebo...
BC Week In Review | Nov 22, 2010
Clinical News

V-5 Immunitor: Completed Phase IIb enrollment

Immunitor completed enrollment of 120 patients in the double-blind, placebo-controlled, Ukrainian Phase IIb Study imm01 trial to evaluate once-daily oral V5 plus standard of care (SOC) consisting of ethambutol, isoniazid, rifampicin and pyrazinamide for 2...
BC Week In Review | Nov 15, 2010
Clinical News

V-5 Immunitor: Phase II data

An open-label, Ukrainian Phase II trial in 20 chronic HCV patients co-infected with HIV and TB showed that once-daily oral V5 significantly reduced serum ALT levels from 1.72 µmol/mL/hour at baseline to 0.18 µmol/mL/hour at...
BC Week In Review | Sep 27, 2010
Company News

Immune Network, Immunitor deal

Immunitor announced it is in discussions to reverse-merge with Immune Network. Immunitor markets products based on its oral vaccine technology for atherosclerosis, hepatitis B and C virus and HIV. Further terms were not disclosed. Immune...
BC Week In Review | Feb 3, 2003
Clinical News

V-1 Immunitor: Phase II

In a placebo-controlled Thai Phase II trial in 35 HIV-negative volunteers, 20 volunteers given V-1 had a 28.2% and 17.5% increase in the number of CD4 and CD8 T cells, respectively, compared to no increase...
Items per page:
1 - 9 of 9
BC Week In Review | Aug 15, 2011
Clinical News

V7: Phase II started

Immune Network said its Immunitor Inc. business began the double-blind, Ukrainian Phase II imm02 trial to evaluate once-daily oral V7 plus standard of care (SOC) vs. placebo plus SOC in about 40 TB patients. Immune...
BC Week In Review | Feb 7, 2011
Company News

Immune Network, Immunitor deal

Immune Network plans to acquire Immunitor in a stock exchange deal. Immune Network will receive 50% of Immunitor's stock in exchange for 50 million Immune Network shares, valued at $2.1 million based on Immune Network's...
BC Week In Review | Jan 31, 2011
Clinical News

V-5 Immunitor: Interim Phase IIb data

Interim data from 34 patients at a second clinical site in the ongoing, double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard of care (SOC) led to a significantly higher...
BC Week In Review | Jan 3, 2011
Clinical News

V-5 Immunitor: Interim Phase IIb data

Interim data from 55 evaluable patients in the double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard of care (SOC) met the primary endpoint of a significantly greater proportion of...
BC Extra | Dec 30, 2010
Clinical News

Immunitor's V5 meets TB endpoint

Immunitor Inc. (College Park, Md.) said once-daily oral V5 plus standard of care (SOC) met the primary endpoint of a significantly greater proportion of patients with a negative sputum smear at one month vs. placebo...
BC Week In Review | Nov 22, 2010
Clinical News

V-5 Immunitor: Completed Phase IIb enrollment

Immunitor completed enrollment of 120 patients in the double-blind, placebo-controlled, Ukrainian Phase IIb Study imm01 trial to evaluate once-daily oral V5 plus standard of care (SOC) consisting of ethambutol, isoniazid, rifampicin and pyrazinamide for 2...
BC Week In Review | Nov 15, 2010
Clinical News

V-5 Immunitor: Phase II data

An open-label, Ukrainian Phase II trial in 20 chronic HCV patients co-infected with HIV and TB showed that once-daily oral V5 significantly reduced serum ALT levels from 1.72 µmol/mL/hour at baseline to 0.18 µmol/mL/hour at...
BC Week In Review | Sep 27, 2010
Company News

Immune Network, Immunitor deal

Immunitor announced it is in discussions to reverse-merge with Immune Network. Immunitor markets products based on its oral vaccine technology for atherosclerosis, hepatitis B and C virus and HIV. Further terms were not disclosed. Immune...
BC Week In Review | Feb 3, 2003
Clinical News

V-1 Immunitor: Phase II

In a placebo-controlled Thai Phase II trial in 35 HIV-negative volunteers, 20 volunteers given V-1 had a 28.2% and 17.5% increase in the number of CD4 and CD8 T cells, respectively, compared to no increase...
Items per page:
1 - 9 of 9